SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Vazquez-Perez S, Aragoncillo P, de Las HN, Navarro-Cid J, Cediel E, Sanz-Rosa D, et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant 2001; 16 Suppl 1: 404.
  • 2
    Eddy AA. Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int 1998; 53: 11829.
  • 3
    Crook ED, Thallapureddy A, Migdal S, Flack JM, Greene EL, Salahudeen A, et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? [review]. Am J Med Sci 2003; 325: 3408.
  • 4
    Grone EF, Walli AK, Grone HJ, Miller B, Seidel D. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994; 107: 113.
  • 5
    Peric-Golia L, Peric-Golia M. Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis 1983; 46: 5765.
  • 6
    Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 32: 6717.
  • 7
    Wellmann KF, Volk BW. Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long term studies. Lab Invest 1971; 24: 14455.
  • 8
    Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats [published erratum appears in Kidney Int 1988;33:1216]. Kidney Int 1988; 33: 66772.
  • 9
    Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 36774.
  • 10
    Joles JA, van Goor H, van der Horst ML, van Tol A, Weening JJ, Koomans HA. Ovariectomy decreases plasma triglyceride levels and both prevents and alleviates glomerular disease in uninephrectomized female analbuminemic rats. J Am Soc Nephrol 1996; 7: 118997.
  • 11
    Washio M, Nanishi F, Onoyama K, Okuda S, Fujishima M. Effects of anti-hyperlipidaemic agent or dietary protein restriction on progressive renal deterioration in adriamycin-induced nephropathy in rats. Int Urol Nephrol 1993; 25: 295303.
  • 12
    Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities study. Kidney Int 2000; 58: 293301.
  • 13
    Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 208491.
  • 14
    Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995; 26: 6705.
  • 15
    Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 190815.
  • 16
    Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 9981004.
  • 17
    Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26: 14027.
  • 18
    Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 2609.
  • 19
    Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. II. Predictor variables for mortality. J Rheumatol 1995; 22: 126570.
  • 20
    Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 106570.
  • 21
    Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989; 16: 42741.
  • 22
    Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 213743.
  • 23
    Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 45461.
  • 24
    Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 85963.
  • 25
    Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 295763.
  • 26
    Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 5339.
  • 27
    Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 12647.
  • 28
    Golbus J, McCune WJ. Lupus nephritis: classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am 1994; 20: 21342.
  • 29
    Goulet JR, MacKenzie T, Levinton C, Hayslett JP, Ciampi A, Esdaile JM. The longterm prognosis of lupus nephritis: the impact of disease activity. J Rheumatol 1993; 20: 5965.
  • 30
    Wallace DJ, Podell TE, Weiner JM, Cox MB, Klinenberg JR, Forouzesh S, et al. Lupus nephritis: experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982; 72: 20920.
  • 31
    Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 2001; 941: 1926.
  • 32
    Nossent HC, Swaak TJ, Berden JH, and the Dutch Working Party on SLE. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Med 1990; 89: 16974.
  • 33
    Cortes-Hernandez J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balada E, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 28796.
  • 34
    Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 14866.
  • 35
    Dooley MA, Hogan S, Jennette C, Falk R, and the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 118895.
  • 36
    Steinberg AD, Madias NE, Harrington JT, Levey AS, Madaio MP, Szer I, et al. The treatment of lupus nephritis. Kidney Int 1986; 30: 76987.
  • 37
    Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus [review]. Am J Med 1996; 101: 1007.
  • 38
    Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990; 16: 18995.
  • 39
    Clark WF, Moist LM. Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease [review]. Lupus 1998; 7: 64953.
  • 40
    Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus [review]. Am J Kidney Dis 1993; 21: 28.
  • 41
    Urowitz MB, Gladman DD. Accelerated atheroma in lupus: background. Lupus 2000; 9: 1615.
  • 42
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 43
    Hemels ME, Bennett HA, Bonari L, Han D, Traverso ML, Einarson TR. HOPE study impact on ACE inhibitors use. Ann Pharmacother 2003; 37: 6405.
  • 44
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 45
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 46
    Tandon A, Ibanez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004; 50: 39416.
  • 47
    Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, and the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 115662.
  • 48
    SAS/STAT software version 9.1. Cary (NC): SAS Institute; 2002.
  • 49
    McAlindon T, Giannotta L, Taub N, D'Cruz D, Hughes G. Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 7204.
  • 50
    Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002; 62: 17439.